NLRP3 and schistosomiasis: The main purpose of this study was to use NLRP3 inflammasome inhibitor, MCC950, to block liver granuloma and fibrosis that resulted from S. japonicum in order to uncover the underlying molecular mechanism and potential treatments for schistosomiasis.